IP Library › Granted Patent US 11,186,638
Granted Patent B2
US 11,186,638 · App. 15/867,364 · Granted Nov 30, 2021

Anti-αβTCR antibody

Inventors: Daniel Snell (Thalwil, CH); Andreas Menrad (Ely, GB); Gina Lacorcia (Concord, MA); Srinivas Shankara (Shrewsbury, MA); Huawei Qiu (Westborough, MA); Clark Pan (Sudbury, MA); Benjamin Kebble (Zurich, CH)
Assignee: GENZYME CORPORATION
C07K16/2809C07K16/2893C07K2317/24C07K2317/31C07K2317/71C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,638
App. No.
15/867,364
Granted
Nov 30, 2021
Kind
B2
Abstract

The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

Claims (15)

1. A method of suppressing a T cell-mediated response in a subject, the method comprising administering to a subject in need thereof an effective amount of a humanized monoclonal antibody specific for human αβTCR/CD3 complex, wherein the humanized monoclonal antibody comprises:

(a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 12, 13, 15, and 16,

(b) a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 14, and

wherein the T cell-mediated response is involved in a condition selected from the group consisting of tissue transplantation, tissue grafting, multiple sclerosis, and type 1 diabetes,

thereby suppressing the T cell-mediated response in the subject.

2. The method according to claim 1 , wherein the humanized monoclonal antibody further comprises a constant region of human origin.

3. The method according to claim 2 , wherein the humanized monoclonal antibody further comprises an Fc modification which reduces Fcγ receptor binding.

4. The method according to claim 3 , wherein the Fc modification comprises multiple mutations selected from the group consisting of N297Q/S298N/Y300S, S298N/T299A/Y300S and S298N/Y300S.

5. The method according to claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 15 and 16.

6. The method according to claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 16.

7. The method according to claim 3 , wherein the Fcγ receptor is selected from the group consisting of FcγRIIIa and FcγRI.

8. The method according to claim 7 , wherein the Fc modification is selected from the group consisting of N297Q/S298N/Y300S, S298N/T299A/Y300S and S298N/Y300S.

9. The method according to claim 8 , wherein the Fc modification is S297N/T299A/Y300S.

10. The method according to claim 8 , wherein the Fc modification is S298N/T299A/Y300S.

11. The method according to claim 8 , wherein the Fc modification is S298N/Y300S.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2021
From: SNELL, DANIEL; MENRAD, ANDREAS; LACORCIA, GINA; SHANKARA, SRINIVAS; QIU, HUAWEI; PAN, CLARK; KEBBLE, BENJAMIN
To: GENZYME CORPORATION
Reel/Frame 057919/0838 →
Continuity (3)
Division 14241099
Provisional Application 61533510 · Sep 12, 2011
Related Publication 20180237522A1 · Aug 23, 2018
Cited By (5)
US 12,365,734 US 12,503,498 US 12,565,529 US 12,612,458 US 12,674,003